

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO.   | FILING DATE   | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |  |
|---|---------------|----------------------|-------------------------|------------------|--|
| 09/582,719  | 08/22/2000    | Margret Hoehe        | 101195-2                | 8381             |  |
| 75  | 90 04/07/2003 |                      |                         |                  |  |
| Bruce S Londa Norris McLaughlin & Marcus 220 EAST 42 nd STREET 30th FLOOR |               |                      | EXAMINER                |                  |  |
|   |               |                      | BRANNOCK, MICHAEL T     |                  |  |
| New York, NY  | 10017         |                      | ART UNIT                | PAPER NUMBER     |  |
|   |               |                      | 1646                    |                  |  |
|   |               |                      | DATE MAILED: 04/07/2003 | de               |  |

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.: <u>09582719</u>

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

| X     | <ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's<br/>attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR<br/>18230, May 1, 1990.</li> </ol>  |  |  |  |  |  |  |  |
|-------|--|--|--|--|--|--|--|--|
|       | <ol><li>This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence<br/>Listing" as required by 37 C.F.R. 1.821(c).</li></ol>   |  |  |  |  |  |  |  |
|       | 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).  |  |  |  |  |  |  |  |
| X     | 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the Raw Sequence Listing Error Report.            |  |  |  |  |  |  |  |
|       | <ol> <li>The computer readable form that has been filed with this application has been found to be damaged<br/>and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute<br/>computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</li> </ol> |  |  |  |  |  |  |  |
|       | 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).   |  |  |  |  |  |  |  |
|       | 7. Other:  |  |  |  |  |  |  |  |
| Аp    | Applicant Must Provide:  |  |  |  |  |  |  |  |
| X     | An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".  |  |  |  |  |  |  |  |
| X     | An initial or <u>substitute</u> paper copy of the "Sequence Listing", <u>as well as an amendment directing its entry into the specification</u> .  |  |  |  |  |  |  |  |
| х     | A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).   |  |  |  |  |  |  |  |
| For   | questions regarding compliance to these requirements, please contact:  |  |  |  |  |  |  |  |
| For   | Rules Interpretation, call (703) 308-4216  |  |  |  |  |  |  |  |
| For   | For CRF Submission Help, call (703) 308-4212   |  |  |  |  |  |  |  |
| E ~ = | Patentln software help, call (703) 308-4212  |  |  |  |  |  |  |  |

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DEA/FCE-1994

| SERIAL NUMBER | FILING DATE | FIRST NAMED APPLICANT |   |                  |                    |
|---------------|-------------|-----------------------|---|------------------|--------------------|
| 09582719      |             |                       |   | A                | TTORNEY DOCKET NO. |
|               |             |                       |   | EXAMINER         |                    |
|               |             |                       |   | Michael Brannock |                    |
|               |             |                       |   | ART UNIT         | PAPER NUMBER       |
|               |             |                       |   | 1646             | 19                 |
|               |             |                       | 1 | DATE MAILED:     |                    |

## Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents Applicant's response to the Office Action of 2/15/02 is noted, however, the reply filed on 1/3/03 is not fully responsive to the prior Office action. Applicant is again reminded that the specification makes reference to specific polynucleotide and polypeptide sequences; these references must contain a sequence identifier of the form: SEQ ID NO: X, see Figure 2, for example. Note: a sequence identifier relating to sequences in a figure may be present either in the figure or in the Brief Description of the Figures. Additionally, the computer readable form (CRF) of the new raw sequence listing was found to contain errors, see attached Raw Sequence Listing Error Report.

Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael T. Brannock, Ph.D., whose telephone number is (703) 306-5876. The examiner can normally be reached on Mondays through Fridays from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Michael T. Brannock April 4, 2003

attch: RSL Error Report and Notice to Comply

SUPERVISORY PATENT EYAMINES

TECHNIOLOGY "